Table 1.
Patient characteristics by diabetes status
| Tumor characteristics | All patients, N (%) | Nondiabetic, N (%) | Diabetic, N (%) | P |
|---|---|---|---|---|
| Age (years) | ||||
| <50 | 60 (11.0) | 52 (13.0) | 8 (2.1) | 0.075 |
| 50–60 | 161 (29.6) | 120 (30.0) | 41 (31.9) | |
| 60–70 | 207 (38.1) | 147 (36.8) | 60 (66.0) | |
| >70 | 116 (21.3) | 81 (20.3) | 35 (24.3) | |
| Race | ||||
| White | 473 (86.9) | 363 (90.8) | 110 (76.4) | <0.001 |
| Black | 22 (4.0) | 12 (3.0) | 10 (6.9) | |
| Hispanic | 33 (6.1) | 15 (3.8) | 18 (12.5) | |
| Others | 16 (2.9) | 10 (2.5) | 6 (4.2) | |
| Sex | ||||
| Male | 314 (57.7) | 221 (55.3) | 93 (64.6) | 0.052 |
| Female | 230 (42.3) | 179 (44.8) | 51 (35.4) | |
| BMI | ||||
| <25 | 228 (44.4) | 178 (47.2) | 50 (36.8) | 0.005 |
| 25.1–30 | 197 (38.4) | 146 (38.7) | 51 (37.5) | |
| >30 | 88 (17.2) | 53 (14.1) | 35 (25.7) | |
| Perineural invasion | ||||
| No | 71 (13.1) | 60 (15.0) | 11 (7.6) | 0.025 |
| Yes | 473 (86.9) | 340 (85.0) | 133 (92.4) | |
| Lymphovascular invasion | ||||
| No | 177 (35.3) | 137 (36.9) | 40 (30.5) | 0.188 |
| Yes | 325 (64.7) | 234 (63.1) | 91 (69.5) | |
| T stage | ||||
| T1 | 43 (7.9) | 35 (8.8) | 8 (5.6) | 0.248 |
| T2 | 23 (4.2) | 20 (5.0) | 3 (2.1) | |
| T3 | 468 (86.2) | 337 (84.5) | 131 (91.0) | |
| T4 | 9 (1.7) | 7 (1.8) | 2 (1.4) | |
| Node status | ||||
| No | 190 (34.9) | 135 (33.8) | 55 (38.2) | 0.337 |
| Yes | 354 (65.1) | 265 (66.3) | 89 (61.8) | |
| Margin status | ||||
| Negative | 426 (78.3) | 315 (78.8) | 111 (77.1) | 0.677 |
| Positive | 118 (21.7) | 85 (21.3) | 33 (22.9) | |
| Differentiation | ||||
| Well–moderate | 302 (56.9) | 227 (58.1) | 75 (53.6) | 0.358 |
| Poor | 229 (43.1) | 164 (41.9) | 65 (46.4) | |
| Tumor site | ||||
| Pancreas head and neck | 439 (82.2) | 327 (83.2) | 112 (79.4) | 0.315 |
| Body and tail | 95 (17.8) | 66 (16.8) | 29 (20.6) | |
| Tumor size (cm) | ||||
| <2 | 145 (27.8) | 109 (28.4) | 36 (26.1) | 0.620 |
| 2.1–3.0 | 192 (36.2) | 137 (35.7) | 52 (37.7) | |
| >3.0 | 186 (36.0) | 136 (36.0) | 50 (36.2) | |
| CA19-9 (U/mL) | ||||
| <47 | 152 (33.8) | 119 (36.0) | 33 (27.7) | 0.160 |
| 48–1000 | 249 (55.3) | 180 (54.4) | 69 (58.0) | |
| >1000 | 49 (10.9) | 32 (9.7) | 17 (14.3) | |
Numbers do not add to the total number of patients for BMI, lymphovascular invasion, T stage, tumor grade, tumor site, and CA19-9 because of missing information.